Medicare prior authorization changes in 2026: what’s new
CMS has already finalized some prior authorization changes, and it has also proposed new drug-related rules that are not final yet. Here’s how the new timeline works, who may feel it, and what to do if care is delayed or denied.
Medicare’s prior authorization rules are changing, but not all at once. Some requirements were already finalized in 2024 and began taking effect in 2026, while a new 2026 proposal covering drugs is still open to public comment and could change before it becomes final.
For patients and families, the practical takeaway is simple: more care decisions may move toward electronic review and faster responses, but prior authorization is still likely to affect access, paperwork, and timing for some services and drugs.
What is final, and what is still proposed
The Centers for Medicare & Medicaid Services, or CMS, has two different policy tracks underway. One is a 2024 final rule on interoperability and prior authorization. The other is a 2026 proposed rule that would extend some of those ideas to drugs and add new requirements for certain payer types.
The key distinction matters: a final rule is in effect on the schedule CMS set, while a proposed rule is not yet locked in. CMS says the new drug proposal is open for public comment until June 15, 2026.
What the 2026 drug proposal would do
In plain language, the proposal would push more prior authorization requests for drugs into electronic systems. CMS says it wants affected payers to support electronic prior authorization and use standard data exchange tools so doctors and plans can send and receive requests more efficiently.
CMS says the proposal would apply to Medicare Advantage plans, Medicaid fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and marketplace plans sold on the federally facilitated exchanges. The proposal also adds small-group market QHP issuers on the federally facilitated SHOP exchange.
If finalized as written, the drug-related electronic prior authorization changes would begin October 1, 2027. For drug coverage under a pharmacy benefit, CMS also proposes using existing prescription claim standards that align with Medicare Part D practices.
What the 2024 final rule already set in motion
CMS finalized broader interoperability and prior authorization changes in January 2024. According to CMS, impacted payers must implement some provisions by January 1, 2026, and most API-related requirements by January 1, 2027.
Those earlier rules were designed to improve data sharing through APIs, make prior authorization more transparent, and reduce administrative burden for patients, clinicians, and plans. In practical terms, that means more requests and responses are expected to happen through standardized electronic systems rather than by fax or scattered manual paperwork.
How WISeR fits in
Separately, CMS launched the WISeR model in traditional Medicare on January 1, 2026. KFF reports that the model tests new prior authorization requirements in six states over a six-year period.
This is important because traditional Medicare has historically used prior authorization less often than Medicare Advantage and many private plans. The model is meant to test whether technology can help review certain services more quickly and consistently, but its real-world effect on access is still being watched.
Who may feel the effects most
Patients and caregivers may notice extra steps before a test, device, procedure, or drug is approved. That can mean waiting for a decision, gathering records, or following up when paperwork stalls.
Doctors, hospitals, and pharmacies may feel the biggest workflow changes. More electronic prior authorization can reduce some manual back-and-forth, but it can also mean more documentation standards, new software requirements, and more time spent checking coverage rules.
People with chronic illness, complex treatment needs, or limited ability to navigate insurance systems may be more likely to feel delays if requests are incomplete or if a plan asks for more information.
What to do if care is delayed or denied
If a prior authorization request is delayed or denied, ask for the reason in writing and keep copies of all paperwork. If possible, ask the clinician’s office or pharmacy to help resubmit the request with the missing documentation.
It can also help to ask whether the plan wants a different form, more clinical notes, or proof that a lower-cost option was tried first. If the plan gives a denial, ask about the appeal process and the deadline to file it.
Because Medicare, Medicaid, Marketplace, and employer plans can all handle prior authorization differently, the exact steps can vary by plan and state.
What remains uncertain
The 2026 drug proposal is not final yet, so CMS could revise it after public comment. And while WISeR is already underway, it is still too early to know how much it will affect access, delays, or denials in traditional Medicare.
For now, the most useful approach is to watch the dates closely: January 1, 2026 and January 1, 2027 for the finalized interoperability rule, and October 1, 2027 if the drug proposal is finalized on its current timeline.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
